drugset / Trial / NCT05256641
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
Timeline
- Start
- 2023-01-23
- Primary completion
- 2027-01-31
- Completion
- 2028-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | — | Oral |